Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2005-04-15
2009-10-27
Parkin, Jeffrey S. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S188100, C424S199100
Reexamination Certificate
active
07608273
ABSTRACT:
Novel HIV vaccines comprising an avirulent and non-cytolytic recombinant HIVs are provided.
REFERENCES:
patent: 7067134 (2006-06-01), Kang et al.
patent: WO 94/17825 (1994-08-01), None
patent: WO 00 09703 (2000-02-01), None
Li, Y., et al., 1994, “Control of expression, glycosylation, and secretion of HIV-1 gp120 by homologous and heterologous signal sequences”, Virol. 204:266-278.
Jamieson, B. D., et al., 1994, “Requirement of human immunodeficiency virus type 1 nef for in vivo replication and pathogenicity”, J. Virol. 68(6):3478-3485.
Haynes, B. F., 1996, “HIV vaccines: where we are and where we are going”, The Lancet 348:933-37.
Burton, D. R., and J. P. Moore, 1998, “Why do we not have an HIV vaccine and how can we make one?”, Nat. Med. Vac. Suppl. 4(5):495-98.
Moore, J. P., and D. R. Burton, 1999, “HIV-1 neutralizing antibodies: how full is the bottle?”, Nat. Med. 5(2):142-44.
Feinberg, M. B., and J. P. Moore, 2002, “AIDS vaccine models: challenging challenge viruses”, Nat. Med. 8(3):207-10.
McMichael, A. J., and T. Hanke, 2003, “HIV vaccines 1983-2003”, Nat. Med. 9(7):874-80.
Desrosiers, R. C., 2004, “Prospects for an AIDS vaccine”, Nat. Med. 10(3):221-223.
Banda, N. K. et al., “Crosslinking, CD4 by human immunodeficiency virus gp120 primes T cells for activation-induced apoptosis”,J. Exp. Med., 176(4):1099-1106 (abstract provided)(1992).
Burton, D. R. et al., “Why do we not have an HIV vaccine and how can we make one”,Nat. Med. Vac. Suppl., 4(5):495-98 (1998).
Chakrabarti, et al., Proceedings of the National Academy of Sciences of USA, 93(18):9810-9815 (1996).
Daniel, M. D. et al., “Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene”,Science, 258(5090):1938-41 (abstract provided)(1992).
Haynes, B. F., “HIV Vaccines: where are we and where are we going?”,Lancet, 348:933-37 (1996).
Haynes, B. F. et al., “Update on the issues of HIV vaccine development”,Ann. Med., 28-39-41 (1996).
Jassoy, C. et al., “Human Immunodeficiency virus type 1-specific cytotoxic T lymphocytes . . . ”,J. Virol., 67(5):2844-2852 (1989).
Laurent-Crawford, A. G. et al., “Membrane expression of HIV envelope glycoproteins triggers apoptosis in CD4 cells”,AIDS Res. Human Retrovir., 9(8):761-773 (abstract provided)(1993).
Lee, T.-H., “Acquired immunodeficiency disease vaccines: design and development”,AIDS: Biology, Diagnosis, Treatment, and Prevention, DeVita, Jr., V. T., et al., eds., fourth eds., 605-616 (1997).
Letvin, N. L., “Progress in the development of an HIV-1 vaccine”,Science, 280:1875-1880 (1998).
Li, Y. et al., “Control of expression, glycosylation, and secretion of HIV-1 gp120 by homologous and heterologous signal sequences”,Virol., 204:266-278 (1994).
Li, Y. et al., “Effects of inefficient cleavage of the signal sequence of HIV-1 gp120 on its association with calnexin, folding and intracellular transport”,Proc. Natl. Acad. Sci. USA, 93:9606-9611 (1996).
Siliciano, R. F. et al., “Analysis of host-virus interactions in AIDS with anti-gp120 T cell clones: effect of HIV sequence variation and a mechanism for CD4+ cell depletion”,Cell, 54(4):561-575 (abstract provided)(1988).
Stevenson, M. et al., “Envelope glycoprotein of HIV induces interference and cytolosis resistance in CD4+ cells: mechanism for persistence in AIDS”,Cell, 53(3):483-496 (abstract provided)(1988).
Weinhold, K. et al., “HIV-1 gp120-mediated immune suppression and lymphocyte destruction in the absence of viral infection”,J. Immunol., 142(9):3091-3097 (abstract provided)(1989).
Daniel, M. D. et al., “Protective Effects of a Live Attenuated SIV Vaccine with a Deletion in thenefGene,” Science 258:1938-1941 (1992).
Supplementary European Search Report for EP 06 72 7538 dated Nov. 21, 2008.
Kang Chil-Yong
Li Yan
Foley & Hoag LLP
Parkin Jeffrey S.
University of Western Ontario
LandOfFree
Recombinant lentivirus encoding modified GP 120 signal... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant lentivirus encoding modified GP 120 signal..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant lentivirus encoding modified GP 120 signal... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4109938